Uterine Sarcoma: Retrospective Study From A Single institute

Area of Science:

• Gynecologic Oncology
• Surgical Pathology
• Cancer Research

Background:

• Uterine sarcomas constitute 1% of gynecologic malignancies and are a heterogeneous group of tumors.
• Optimal treatment strategies remain debated due to the rarity of these tumors and a lack of randomized controlled trials.
• Surgical management without spill is the standard primary treatment, with diagnosis often occurring postoperatively.

Purpose of the Study:

• To analyze the clinicopathological characteristics of uterine sarcomas.
• To identify prognostic factors influencing survival outcomes.
• To evaluate treatment details and survival rates for different uterine sarcoma types.

Main Methods:

• Retrospective analysis of 59 uterine sarcoma patients who underwent surgery.
• Adjuvant chemotherapy or radiation therapy administered based on histopathology and FIGO stage.
• Patient follow-up every three months for two years, then every six months; calculation of disease-free survival (DFS) and overall survival (OS).

Main Results:

• Uterine sarcomas are rare, aggressive tumors, with most presenting at an early stage.
• Surgery is the primary treatment modality, though the role of adjuvant radiation therapy is controversial.
• Tumor stage was identified as the most critical prognostic factor.

Conclusions:

• Tumor stage is the most important prognostic factor in uterine sarcomas.
• Surgery remains the cornerstone of treatment for these rare and aggressive uterine tumors.
• Further research is needed to clarify the role of adjuvant therapies.